Takeda has announced that the U.S. Food and Drug Administration has approved ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 in adults. This milestone marks the first and only medicine to target the root cause of the disease. Julie Kim, president and CEO of Takeda, said the approval is a turning point for the narcolepsy type 1 community. The drug will be available after the Drug Enforcement Administration completes its scheduling process.
ORZEYFUL is an oral medication that acts as an orexin receptor 2 agonist. It works by restoring signaling to address the orexin deficiency that causes the disease. Unlike previous treatments that only address symptoms, this medication treats the condition more holistically. It represents the first treatment in its class to directly address the underlying issue in this chronic neurological disorder.
Clinical Trial Results and Impact on Patients
Clinical Trial Success
The FDA approved ORZEYFUL based on findings from two global Phase 3 trials named FirstLight and RadiantLight. These studies found that oveporexton significantly improved various symptoms of narcolepsy type 1. Patients experienced better control over daytime sleepiness, reduced cataplexy episodes, and enhanced overall quality of life. These results confirm the drug's effectiveness in managing the full range of the condition.
Julie Flygare, President and CEO of Project Sleep and someone who lives with narcolepsy type 1, praised the approval as a historic moment. She said it offers new treatment choices and brings hope to the community. Dr. Emmanuel Mignot, the lead investigator in the Phase 3 program, added that the drug changes the conversation between doctors and patients. Instead of just managing individual symptoms, they can now focus on the root cause of the disease.
Narcolepsy type 1 is a rare, chronic neurological disease affecting an estimated 120,000 people in the U.S. It is characterized by the loss of orexin, a brain chemical essential for regulating wakefulness and sleep. Those living with the condition endure excessive daytime sleepiness, cataplexy (a sudden loss of muscle tone), cognitive symptoms, and disrupted nighttime sleep. These symptoms can severely impact work, education, and social interactions, making it critical to have effective treatment options.
A New Treatment Paradigm
Until now, available treatments have primarily focused on symptom relief. ORZEYFUL, as a first-in-class orexin treatment, has the potential to redefine care for those with narcolepsy type 1. Dr. Mignot noted that this is the first and only approved orexin therapy to treat the full range of the disease. He emphasized that this approval opens the door for a broader dialogue about treatment options and outcomes.
Andy Plump, President of Research & Development at Takeda, said orexin holds great promise as a therapeutic pathway. He believes ORZEYFUL is just the beginning of a new class of drugs. Takeda is already looking into its potential for treating other disorders. The DEA is currently reviewing the controlled substance classification for ORZEYFUL, which should be finalized in 90 days. After that, the drug will be provided through a specialty pharmacy to U.S. doctors and patients.
Takeda stated that the FDA approval of ORZEYFUL is unlikely to impact its full-year financial forecast for the fiscal year ending March 31, 2027. The approval followed a successful submission of the new drug application for oveporexton. The FDA accepted and granted priority review to the application on February 10, 2026, as stated in an earlier press release.
Safety and Side Effects
The most common side effects of ORZEYFUL include trouble sleeping (insomnia), frequent urination, and increased saliva production. These effects were generally manageable and consistent across clinical trials. The drug works by selectively activating orexin receptor 2 to restore signaling and treat the underlying orexin deficiency in narcolepsy type 1. This mechanism helps promote wakefulness and reduce abnormal REM-sleep like symptoms, such as cataplexy.
In a broader context, the approval of ORZEYFUL reflects a shift in medical treatment toward addressing the root causes of chronic diseases. As Takeda continues to advance its research and development pipeline, the company aims to explore the therapeutic potential of orexin in various conditions, potentially benefiting more patients in the future.